The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I results of gunagratinib (ICP-192), a highly selective irreversible FGFR 1-4 inhibitor in patients with head and neck cancer harboring FGF/FGFR gene aberrations.
 
Ye Guo
Honoraria - BMS; Merck Serono; MSD; Roche
Consulting or Advisory Role - Bayer; Merck Serono; MSD; Roche
 
Qun Li
No Relationships to Disclose
 
Wenbo Tang
No Relationships to Disclose
 
Fengjuan Lin
No Relationships to Disclose
 
Junli Xue
No Relationships to Disclose
 
Liqiong Xue
No Relationships to Disclose
 
Xiaoxiao Ge
No Relationships to Disclose
 
Wei Zhao
No Relationships to Disclose
 
Wei Zhou
Employment - Hansoh; Innocare
Stock and Other Ownership Interests - Innocare
 
Renbin Zhao
Employment - Innocare
Leadership - Innocare
Stock and Other Ownership Interests - Innocare
 
Bin Zhang
Employment - Innocare
Stock and Other Ownership Interests - Innocare
 
Jin Li
Honoraria - AstraZeneca; Bristol-Myers Squibb; Hengrui Pharmaceutical; MSD
Consulting or Advisory Role - Hengrui Pharmaceutical; Lanova